ASTROCYTOMA, IDH-MUTANT, GRADE 3
Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 3 explained in plain language.
Never miss a new study
Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 3 trials appear
Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope in fight against brain cancer: major trial tests targeted drug
Disease control Not yet recruitingThis study is testing if adding a new targeted drug, vorasidenib, to the usual treatment (radiation and chemotherapy) works better for people with a specific type of newly diagnosed brain tumor called grade 3 astrocytoma. About 408 patients will receive either the new drug combin…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New Two-Pronged attack tested for tough brain cancers
Disease control Not yet recruitingThis study is testing a combination of two drugs, retifanlimab and DFMO, for people with aggressive brain tumors that have started growing again. The first goal is to find a safe and tolerable dose of DFMO to give with retifanlimab. Researchers will then see if this combination h…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC